CTMX — CytomX Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1501989 ·
Last close
$1.94
Market Cap
$422.93M
52W High
$8.21
52W Low
$1.90
ADV30
4,617,593
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 1,688,000 | — | -23,502,000 | -19,998,000 | 364,679,000 | 33,963,000 | 79,791,000 |
| Jun 2026 | 1,418,000 | — | -23,781,000 | -20,666,000 | 381,226,000 | 17,224,000 | 79,158,000 |
| Mar 2026 | 10,258,000 | — | -19,672,000 | -18,248,000 | 359,358,000 | 28,828,000 | 39,414,000 |
| Dec 2025 | 663,000 | — | -27,932,000 | -26,510,000 | 151,566,000 | 12,667,000 | 52,558,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,408,000
Investing CF
$-200,804,000
Financing CF
$251,894,000
CapEx
$-347,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.28
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-750,863,000
Inventory
—
Receivables
$37,494,000
ST Investments
$313,056,000
EBIT TTM
$-87,153,000
Pretax Income TTM
$-79,422,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$14,028,000
EBITDA
$-93,664,000
Free Cash Flow
$-50,412,376
Enterprise Value
$133,838,776
Total Cash
$347,980,000
Total Debt
$4,388,000
Shares Out
218,004,920
Trailing EPS
$-0.51
Book Value
$1.31
ROE
-43.6%
ROA
-22.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 76,201,000 | -22,364,000 | -17,368,000 | 151,566,000 | 52,558,000 | 99,008,000 | -75,587,000 |
| Dec 2024 | 138,103,000 | 24,995,000 | 31,869,000 | 120,533,000 | 120,989,000 | -456,000 | -86,231,000 |
| Dec 2023 | 101,214,000 | -6,484,000 | -569,000 | 201,792,000 | 249,239,000 | -47,447,000 | -56,035,000 |
| Dec 2022 | 53,163,000 | -101,335,000 | -99,317,000 | 260,891,000 | 346,642,000 | -85,751,000 | -110,788,000 |
TTM Snapshot
Revenues TTM
$18,302,000
NetIncome TTM
$-79,653,000
OpCashFlow TTM
—
Assets (Latest)
$381,226,000
Forward EPS
$-0.52
Max Pain — expiry 2028-01-21
max pain strike: $1.50 · spot: $1.88 · call oi: 1,617 · put oi: 89
Expected Move to 2028-01-21:
±$2.10
(111.70%) —
implied range
$-0.22 –
$3.98
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRTA | PROTHENA CORP PUBLIC LTD CO | $424.15M | $8.26 | — |
| OVID | Ovid Therapeutics Inc. | $418.98M | $2.22 | — |
| OCS | Oculis Holding AG | $417.01M | $7.51 | — |
| AVTX | Avalo Therapeutics, Inc. | $412.28M | $7.13 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $437.41M | $6.62 | — |
News headlines (Yahoo Finance, 1h cache)
CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
2026-11-17 21:15 · Yahoo
CytomX (CTMX) Q3 2026 Earnings Call Transcript
2026-11-06 08:58 · Yahoo
CytomX Therapeutics Q3 Earnings Call Highlights
2026-11-06 03:14 · Yahoo
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
2026-11-05 21:45 · Yahoo
CytomX Therapeutics: Q3 Earnings Snapshot
2026-11-05 21:31 · Yahoo
CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
2026-11-05 21:15 · Yahoo
CytomX Therapeutics to Present at Upcoming November Investor Conferences
2026-11-02 13:00 · Yahoo
CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026
2026-10-29 12:00 · Yahoo
CytomX Therapeutics to Present at Upcoming September Investor Conferences
2026-09-01 12:00 · Yahoo
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
2026-08-07 05:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.